Latest News

Latest News

Clinical Trial Results 6 November 2026

Clinical Trial Results 6 November 2026

The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.

Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.

In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...

read more
The Future of Diagnostics Is Molecularly Precise

The Future of Diagnostics Is Molecularly Precise

The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...

read more
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...

read more
Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.

Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.

In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...

read more
The Future of Diagnostics Is Molecularly Precise

The Future of Diagnostics Is Molecularly Precise

The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...

read more
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Who Confirms the Alert Before Dawn?

Who Confirms the Alert Before Dawn?

I practice emergency medicine. Overnight care is where timing funds or fails any sepsis early warning tool. A recommendation that sits unconfirmed for hours is not decision support. It is wallpaper. Confirmation is the intervention Accuracy slides still dominate...

read more
The Model Said No. Who Gets to Overrule It?

The Model Said No. Who Gets to Overrule It?

In rare tumors, oncologists know the usual story. PD-L1 is a weak compass. Tumor mutational burden is often unavailable. The evidence base was never built. So when MD Anderson investigators revisited biopsies from 84 patients in a phase 2 basket trial of pembrolizumab...

read more
Weekly News Roundup | 05 October 2026

Weekly News Roundup | 05 October 2026

Life science news 5 October 2026: four US approvals, three deals and two UK regulatory items. The FDA approved Emcitate, which it calls the first treatment for MCT8 deficiency. The FDA approved a heart valve that can be expanded as a child grows. AstraZeneca agreed to...

read more
Why Periodontitis Matters Beyond Dentistry

Why Periodontitis Matters Beyond Dentistry

In brief: Periodontitis, the advanced form of gum disease, is consistently linked with cardiovascular disease, type 2 diabetes and adverse pregnancy outcomes. Only the diabetes link is supported by treatment trials, in which periodontal therapy lowers HbA1c by about...

read more
Low FODMAP Diet and Disordered Eating in IBS

Low FODMAP Diet and Disordered Eating in IBS

A new study published in September has reinforced how, for people with IBS who have been taught the low FODMAP diet, uncontrolled digestive symptoms and psychological distress can be linked to disordered eating behaviours. It can help us think about how patients are...

read more
Clinical Trials Roundup | 2 October 2026

Clinical Trials Roundup | 2 October 2026

The clinical trial results 2 October 2026 span hepatitis delta, wet macular degeneration, Niemann-Pick disease, COVID-19 and skin cancer. Mirum Pharmaceuticals’ brelovitug met its primary endpoint in chronic hepatitis delta. Kodiak Sciences’ Zenkuda and tabirafusp-ted...

read more
Beyond the Scale: Meaningful Follow-Up in GLP-1 Care

Beyond the Scale: Meaningful Follow-Up in GLP-1 Care

A GLP-1 follow-up appointment can produce a clear number without answering the most important question: how is this person doing? Weight remains relevant in obesity care, but a useful review also creates space for symptoms, everyday function and the practical work of...

read more
How AI Is Redefining the Modern Healthcare Consultation

How AI Is Redefining the Modern Healthcare Consultation

Healthcare in the United States is facing a structural inflection point. Physician burnout remains high. Administrative burdens consume hours that should be spent with patients. Chronic disease rates continue to rise. At the same time, health systems are under...

read more
The Writing Got Cheap. The Checking Did Not

The Writing Got Cheap. The Checking Did Not

Last month I published a cost analysis with wrong numbers in it. Not rounded wrong. I had taken the wrong price list and the wrong tariff for cache writes, and when I recomputed, the headline figure moved. I issued a corrected version and stopped citing the first one....

read more

Further News

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...

Imdelltra Imfinzi Approval: When Could First-Line Use Begin?

Amgen and AstraZeneca presented full DeLLphi-305 results at the ESMO Congress in Madrid. The phase 3 trial added Amgen’s Imdelltra (tarlatamab-dlle) to AstraZeneca’s Imfinzi (durvalumab). It cut the risk of death by 58 per cent in extensive-stage small cell lung...

OOS Investigation: A Solubility-Related HPLC Assay Failure

A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...

Pharma’s Digital Maturity Divide Is Holding Back AI Adoption

AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those...

UK Biotech Venture Capital Nears a Record Year as Seed Funding Shrinks

UK biotech venture capital reached £2.84 billion in the first nine months of 2026. That is more than in any full year from 2022 to 2025. The figures come from the BioIndustry Association (BIA) Q3 2026 financing report, published on 26 October 2026 [1]. The BIA puts...

Connecting ADME and Mouse Models in Preclinical Oncology

In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...

Weekly News Roundup | 26 October 2026

Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...

Melanoma Vaccine Approval: When Could Intismeran Reach Patients?

Melanoma vaccine approval is not yet decided. Merck and Moderna report phase 3 intismeran data and say they are engaging with regulators.

    Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale

    For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as...

    From Regulation to Adoption: What Europe Needs Next for AI in Health

    The UK and EU have reached a pivotal point in the regulation of AI in health. Both have set ambitious goals for protecting patients while enabling innovation, but success will depend on whether regulatory frameworks can be translated into responsible adoption and...

    Clinical Trial Results 23 October 2026

    The clinical trial results 23 October 2026 cover non-infectious uveitis, hidradenitis suppurativa, IgA nephropathy, wet AMD and metastatic colorectal cancer. Priovant’s brepocitinib met its primary endpoint in two Phase 3 trials in non-infectious uveitis. AbbVie’s...

    Fenebrutinib Approval: When Could the FDA Decide on Roche’s MS Drug?

    Roche has not said when the FDA will decide. See the phase 3 data, safety findings and UK NICE status for fenebrutinib.

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.